Anti-CD20 Agents for Multiple Sclerosis: Spotlight on Ocrelizumab and Ofatumumab

[img]
Preview
brainsci-10-00758.pdf - Published Version (660kB) | Preview
Available under license: Creative Commons Attribution

Florou, Despoina, Katsara, M, Feehan, Jack ORCID: 0000-0002-9627-1299, Dardiotis, Efthimios and Apostolopoulos, Vasso ORCID: 0000-0001-6788-2771 (2020) Anti-CD20 Agents for Multiple Sclerosis: Spotlight on Ocrelizumab and Ofatumumab. Brain Sciences, 10 (10). ISSN 2076-3425

Dimensions Badge

Altmetric Badge

Item type Article
URI https://vuir.vu.edu.au/id/eprint/42589
DOI https://doi.org/10.3390/brainsci10100758
Official URL https://www.mdpi.com/2076-3425/10/10/758
Subjects Current > FOR (2020) Classification > 3204 Immunology
Current > FOR (2020) Classification > 3208 Medical physiology
Current > Division/Research > Institute for Health and Sport
Keywords monoclonal antibodies; multiple sclerosis; B-cell therapies; safety
Citations in Scopus 8 - View on Scopus
Download/View statistics View download statistics for this item

Search Google Scholar

Repository staff login